Saturday, October 31, 2026

Cliffs Natural Resources Stock Bearish By 20% In The Last 10 Sessions

Cliffs Natural Resources Stock Bearish By 20% In The Last 10 Sessions

(VIANEWS) - Shares of Cliffs Natural Resources (NYSE: CLF) dropped by a staggering 20.7% in 10 sessions from $22.22 to $17.62 at 14:38 EST on Thursday, following the last session's downward trend. NYSE is jumping 0.97% to $14,804.92, following the last session's downward trend.

Cliffs Natural Resources's last close was $17.66, 48.12% below its 52-week high of $34.04.

About Cliffs Natural Resources

Cleveland-Cliffs Inc. operates as a flat-rolled steel producer in North America. The company offers carbon steel products, such as hot-rolled, cold-rolled, electrogalvanized, hot-dip galvanized, hot-dip galvannealed, aluminized, enameling, and advanced high-strength steel products; stainless steel products; plates; and grain oriented and non-oriented electrical steel products. It also provides tubular components, including carbon steel, stainless steel, and electric resistance welded tubing. In addition, the company offers tinplate products, such as electrolytic tin coated and chrome coated sheet, and tin mill products; tooling and sampling; raw materials; ingots, rolled blooms, and cast blooms; and hot-briquetted iron products. Further, it owns five iron ore mines in Minnesota and Michigan. The company serves automotive, infrastructure and manufacturing, distributors and converters, and steel producers. Cleveland-Cliffs Inc. was formerly known as Cliffs Natural Resources Inc. and changed its name to Cleveland-Cliffs Inc. in August 2017. The company was founded in 1847 and is headquartered in Cleveland, Ohio.

Earnings Per Share

As for profitability, Cliffs Natural Resources has a trailing twelve months EPS of $-0.07.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 42.85%.

Volatility

Cliffs Natural Resources's last week, last month's, and last quarter's current intraday variation average was a negative 3.99%, a negative 1.01%, and a positive 2.69%.

Cliffs Natural Resources's highest amplitude of average volatility was 4.67% (last week), 2.92% (last month), and 2.69% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth declined by 5.8%, now sitting on 23.29B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Cliffs Natural Resources's stock is considered to be oversold (<=20).

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is a negative 117.2% and a negative 98%, respectively.

More news about Cliffs Natural Resources (CLF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com